Phase II trial of gefitinib inpatients with incurable salivary gland cancer.

被引：0
|
作者：
Glisson, BS [1 ]
Blumenschein, G [1 ]
Francisco, M [1 ]
Erasmus, J [1 ]
Zinner, R [1 ]
Kies, M [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：508S / 508S
页数：1
相关论文
共 50 条
  • [1] Phase II trial of anastrazole in combination with gefitinib in women with asymptomatic mullerian cancer.
    Krasner, CN
    Debernardo, RL
    Findley, M
    Penson, R
    Matulonis, U
    Atkinson, T
    Roche, M
    Seiden, MV
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 470S - 470S
  • [2] Phase II study of gefitinib in patients with advanced salivary gland cancers
    Jakob, John A.
    Kies, Merrill S.
    Glisson, Bonnie S.
    Kupferman, Michael E.
    Liu, Diane D.
    Lee, J. Jack
    El-Naggar, Adel K.
    Gonzalez-Angulo, Ana M.
    Blumenschein, George R., Jr.
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2015, 37 (05): : 644 - 649
  • [3] Phase II trial of gefitinib for recurrent or metastatic esophageal or gastroesophageal junction (GEJ) cancer.
    Adelstein, DJ
    Rybicki, LA
    Carroll, MA
    Rice, TW
    Mekhail, T
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 321S - 321S
  • [4] Cabozantinib associated with excessive toxicity for salivary gland cancer in phase II trial
    Reactions Weekly, 2022, 1887 (1) : 9 - 9
  • [5] Gemcitabine (G) combined with gefitinib in patients with inoperable or metastatic pancreatic cancer. A phase II trial
    Fountzilas, G.
    Murray, S.
    Xiros, N.
    Karayannopoulou, G.
    Dafni, U.
    Linardou, H.
    Kalogera-Fountzila, A.
    Bobos, M.
    Koumarianou, A.
    Kosmidis, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] A phase II trial of gefitinib in combination with 5-FU/LV/irinotecan in patients with colorectal cancer.
    Redlinger, M
    Kramer, A
    Flaherty, K
    Sun, W
    Haller, D
    O'Dwyer, PJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 310S - 310S
  • [7] Phase II trial of nintedanib in patients with recurrent or metastatic salivary gland cancer: A multicenter phase II study.
    Kim, Youjin
    Lee, Su Jin
    Park, Keunchil
    Lee, Se-hoon
    Sun, Jong Mu
    Keam, Bhumsuk
    An, Ho Jung
    Cho, Jae Yong
    Kim, Jin-Soo
    Lee, Ha-young
    Kim, HyeRyun
    Lee, Kyoung Eun
    Choi, Moon Young
    Lee, Ki Hyeong
    Ahn, Myung-Ju
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] A phase II umbrella clinical trial of advanced salivary gland cancer based on molecular typing
    Ji, Dongmei
    Guo, Yanjing
    Liu, Xin
    Yang, Yanan
    Sang, Youzhou
    Chen, Guangliang
    Dong, Shu
    Wang, Yulong
    He, Xiayun
    Ying, Hongmei
    Lu, Xueguan
    Wang, Yu
    Hu, Chaosu
    Ji, Qinghai
    Zhang, Lu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Phase II trial of gefitinib combined with docetaxel as first-line therapy in patients with metastatic breast cancer.
    Ciardiello, F
    Troiani, T
    Caputo, F
    de Laurentiis, M
    Tortora, G
    Palmieri, G
    de Vita, F
    Colantuoni, G
    de Placido, S
    Bianco, AR
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 211S - 211S
  • [10] Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial
    William, William N., Jr.
    Feng, Lei
    Ferrarotto, Renata
    Ginsberg, Lawrence
    Kies, Merrill
    Lippman, Scott
    Glisson, Bonnie
    Kim, Edward S.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 77 (06) : 1110 - +
12345